Latest market price and medical insurance reimbursement policy updates for macitentan in 2025

Macitentan (Macitentan) is an oral endothelin receptor antagonist (ERA), mainly used to treat patients with pulmonary arterial hypertension (PAH). It can improve pulmonary artery pressure and right heart function by blocking endothelin receptor-mediated vasoconstriction and vascular remodeling. With the deepening of clinical research and application, macitentan has become one of the important drugs in the treatment of PAH.

In the domestic market, the original drug of macitentan has been launched and included in the medical insurance catalog. The specification is 10mg*30 tablets. Each box is priced at about 4,000 yuan. The addition of medical insurance coverage has greatly reduced the financial burden on patients, enabled more patients with pulmonary hypertension to receive long-term and standardized treatment, and improved the accessibility and clinical utilization of drugs. When patients purchase medicines, they can purchase them through medical insurance designated hospitals and pharmacies and enjoy corresponding reimbursement policies.

In overseas markets, macitentan is also widely used, and generic drugs are already on the market in some regions. For example, the same specification of macitentan (10mg*30tablets) produced by a Lao pharmaceutical factory is priced at more than 300 yuan per box, and its pharmaceutical ingredients are basically the same as the original drug. Due to differences in exchange rates and production costs, overseas generic drugs are relatively cheap, providing a viable alternative for patients who cannot afford original drugs. However, it is still necessary to ensure that the sources of drugs are regular and the quality is controllable.

Overall, 2025The domestic market price of macitentan is stable, and the medical insurance reimbursement policy has covered the original drug, providing an economically feasible long-term treatment plan for patients with pulmonary hypertension. Overseas generic drugs are cheaper, but domestic patients still need to go through formal channels and doctor guidance to use them. In the future, with the further improvement of domestic generic drug research and development and medical insurance policies, it is expected that the accessibility of macitentan will be further improved, bringing a safe, effective and affordable treatment option to more patients.

Reference materials:https://www.drugs.com/